Ipsos Healthcare Launches Syndicated Channel Study
October 1 2018
Ipsos Healthcare has rolled out a syndicated Channel Optimisation Study for seven Autoimmune disease areas, combining actual prescribing data from its Global Therapy Monitors series with analysis of patients’ and doctors’ media use and engagement.
The new study looks at digital and traditional information channels used, which companies / brands are leading in each space and why, using a combination of multi-layered patient social media ‘listening’, and open-ended questions. The disease areas covered are Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Hidradenitis Suppurativa and Non-Radiographic Axial Spondyloarthritis.
Paul O’Meara (pictured), Head of the group’s Syndicated Patient Real World Evidence portfolio, comments: ‘In the digital era, biopharma companies are challenged to understand the most effective digital channels through which to communicate their key messages – both to physicians and patients. The new Channel Optimisation Study gives us a holistic perspective of doctor and patient digital footprints and the influence on prescribing of each. This information can then be linked with prescribing data from Global Therapy Monitors to put these findings into the context of Real World Evidence. The result is truly actionable findings for digital strategies’.
Web site: www.ipsos.com .